{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:51:58Z","timestamp":1790729518942,"version":"4.1.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,8]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>In immune-mediated thrombotic thrombocytopenic purpura (iTTP), patients develop antibodies against ADAMTS13. Most patients exhibit inhibitory antispacer antibodies. Noninhibitory antibodies binding to the carboxy-terminal CUB domains have been suggested to enhance the clearance of ADAMTS13 in iTTP. Furthermore, anti-CUB antibodies induce an open conformation, which has been shown to be an important biomarker for disease severity and relapse risk. We explored whether the introduction of N-glycans in the CUB domains of ADAMTS13 can reduce the binding of pathogenic anti-CUB autoantibodies. The binding of a panel of anti-CUB monoclonal antibodies derived from patients with iTTP, to newly designed N-glycan modified ADAMTS13 CUB domain variants, was assessed by enzyme-linked immunosorbent assay. In addition, a subset of these variants was screened against plasma samples from patients with iTTP, which primarily contain antibodies directed toward the carboxy-terminal domains of ADAMTS13. Introduction of N-glycans at amino acid positions of 1251, 1255, and 1368 in the CUB1\/2 domains of ADAMTS13 can effectively reduce the binding of 6 out of 7 anti-CUB antibodies derived from patients with iTTP. Reduced binding to CUB N-glycan variants was observed in 8 out of 9 patient samples. Binding was decreased from 81% to 47% for NGLY3+CUB-NGLY and 60% to 28% for 5ALA+CUB-NGLY variants. Collectively our findings show that the introduction of N-glycans within the CUB domain of ADAMTS13 can prevent the binding of anti-CUB antibodies in patients with iTTP. Based on these findings, we propose that CUB-NGLY modified ADAMTS13 variants can be used for improved treatment of patients with\u00a0iTTP.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014298","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T20:58:40Z","timestamp":1736974720000},"page":"1728-1737","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["N-glycan shielded CUB domains of ADAMTS13 prevent binding of C-terminal antibodies in patients with immune-mediated TTP"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1828-7957","authenticated-orcid":false,"given":"Tim","family":"Postmus","sequence":"first","affiliation":[{"name":"1Department of Molecular Hematology, Sanquin Research, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Schilder","sequence":"additional","affiliation":[{"name":"1Department of Molecular Hematology, Sanquin Research, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4957-1827","authenticated-orcid":false,"given":"Juliana","family":"Ferreira de Santana","sequence":"additional","affiliation":[{"name":"1Department of Molecular Hematology, Sanquin Research, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4718-1764","authenticated-orcid":false,"given":"Pieter","family":"Langerhorst","sequence":"additional","affiliation":[{"name":"1Department of Molecular Hematology, Sanquin Research, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kaijen","sequence":"additional","affiliation":[{"name":"1Department of Molecular Hematology, Sanquin Research, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[{"name":"2Service d'H\u00e9matologie biologique, H\u00f4pital Lariboisi\u00e8re, Assistance Publique-H\u00f4pitaux de Paris Nord, Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"3Centre de R\u00e9f\u00e9rence des Microangiopathies Thrombotiques, Service d'h\u00e9matologie, H\u00f4pital Saint-Antoine, Assistance Publique-H\u00f4pitaux de Paris and Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0151-337X","authenticated-orcid":false,"given":"B\u00e9rang\u00e8re S.","family":"Joly","sequence":"additional","affiliation":[{"name":"2Service d'H\u00e9matologie biologique, H\u00f4pital Lariboisi\u00e8re, Assistance Publique-H\u00f4pitaux de Paris Nord, Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"4INSERM Unit\u00e9 Mixte de Recherche 1138, Centre de Recherche des Cordeliers, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Veyradier","sequence":"additional","affiliation":[{"name":"2Service d'H\u00e9matologie biologique, H\u00f4pital Lariboisi\u00e8re, Assistance Publique-H\u00f4pitaux de Paris Nord, Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"4INSERM Unit\u00e9 Mixte de Recherche 1138, Centre de Recherche des Cordeliers, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-8277","authenticated-orcid":false,"given":"Karen","family":"Vanhoorelbeke","sequence":"additional","affiliation":[{"name":"5Laboratory for Thrombosis Research, IRF Life Sciences, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4585-2621","authenticated-orcid":false,"given":"Jan","family":"Voorberg","sequence":"additional","affiliation":[{"name":"1Department of Molecular Hematology, Sanquin Research, Amsterdam, The Netherlands"},{"name":"6Department of Experimental Vascular Medicine, Amsterdam UMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"issue":"3","key":"2025040815213738900_bib1","first-page":"536","article-title":"Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management","volume":"10","author":"Sukumar","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"2025040815213738900_bib2","doi-asserted-by":"crossref","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"22","key":"2025040815213738900_bib3","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor\u2013cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2025040815213738900_bib4","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3324\/haematol.2010.036327","article-title":"Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain","volume":"96","author":"Pos","year":"2011","journal-title":"Haematologica"},{"issue":"9","key":"2025040815213738900_bib5","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.019299","article-title":"Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura","volume":"95","author":"Zheng","year":"2010","journal-title":"Haematologica"},{"issue":"8","key":"2025040815213738900_bib6","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ebiom.2015.06.007","article-title":"Pathogenicity of anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura","volume":"2","author":"Thomas","year":"2015","journal-title":"EBioMedicine"},{"issue":"8","key":"2025040815213738900_bib7","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1182\/blood-2009-06-229203","article-title":"An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF","volume":"115","author":"Pos","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2025040815213738900_bib8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1160\/TH04-05-0301","article-title":"The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura","volume":"93","author":"Luken","year":"2005","journal-title":"Thromb Haemost"},{"issue":"11","key":"2025040815213738900_bib9","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.3324\/haematol.2019.226068","article-title":"Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura","volume":"105","author":"Gra\u00e7a","year":"2020","journal-title":"Haematologica"},{"issue":"12","key":"2025040815213738900_bib10","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1016\/j.jtha.2023.08.017","article-title":"Impact of N-glycan mediated shielding of ADAMTS-13 on the binding of pathogenic antibodies in immune thrombotic thrombocytopenic purpura","volume":"21","author":"Postmus","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"19","key":"2025040815213738900_bib11","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1182\/blood.2020007972","article-title":"N-glycan\u2013mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP","volume":"137","author":"Ercig","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2025040815213738900_bib12","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood-2003-12-4165","article-title":"Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura","volume":"103","author":"Klaus","year":"2004","journal-title":"Blood"},{"issue":"17","key":"2025040815213738900_bib13","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1182\/bloodadvances.2020004172","article-title":"Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura","volume":"5","author":"Kangro","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2025040815213738900_bib14","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.jtha.2023.02.011","article-title":"Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura","volume":"21","author":"Underwood","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2025040815213738900_bib15","first-page":"353","article-title":"Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura","volume":"136","author":"Roose","year":"2020","journal-title":"Blood"},{"issue":"21","key":"2025040815213738900_bib16","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/bloodadvances.2021004971","article-title":"Anti-cysteine\/spacer antibodies that open ADAMTS13 are a common feature in iTTP","volume":"5","author":"De Waele","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"2025040815213738900_bib17","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/jth.13149","article-title":"Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTS-13","volume":"13","author":"Deforche","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"2025040815213738900_bib18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/jth.13922","article-title":"An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura","volume":"16","author":"Roose","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"2025040815213738900_bib19","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/S2352-3026(16)30018-7","article-title":"Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy","volume":"3","author":"Mariotte","year":"2016","journal-title":"Lancet Haematol"},{"issue":"3","key":"2025040815213738900_bib20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1160\/TH06-03-0135","article-title":"Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP","volume":"96","author":"Luken","year":"2006","journal-title":"Thromb Haemost"},{"issue":"16","key":"2025040815213738900_bib21","first-page":"eabg4403","article-title":"Crystal structure of ADAMTS13 CUB domains reveals their role in global latency","volume":"7","author":"Kim","year":"2021","journal-title":"Sci\u00a0Adv"},{"issue":"2","key":"2025040815213738900_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/glycob\/cwh008","article-title":"Statistical analysis of the protein environment of N-glycosylation sites: implications for occupancy, structure, and folding","volume":"14","author":"Petrescu","year":"2004","journal-title":"Glycobiology"},{"issue":"24","key":"2025040815213738900_bib23","doi-asserted-by":"crossref","first-page":"14756","DOI":"10.1074\/jbc.270.24.14756","article-title":"The hydroxy amino acid in an Asn-X-Ser\/Thr sequon can influence N-linked core glycosylation efficiency and the level of expression of a cell surface glycoprotein","volume":"270","author":"Kasturi","year":"1995","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"2025040815213738900_bib24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.thromres.2011.03.010","article-title":"Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura","volume":"128","author":"Yamaguchi","year":"2011","journal-title":"Thromb Res"},{"issue":"2","key":"2025040815213738900_bib25","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/jth.15170","article-title":"Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura","volume":"19","author":"Vel\u00e1squez Pereira","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7","key":"2025040815213738900_bib26","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1111\/trf.13583","article-title":"ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model","volume":"56","author":"Ostertag","year":"2016","journal-title":"Transfusion"},{"issue":"7","key":"2025040815213738900_bib27","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/trf.13584","article-title":"ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in\u00a0vitro","volume":"56","author":"Ostertag","year":"2016","journal-title":"Transfusion"},{"issue":"8","key":"2025040815213738900_bib28","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ebiom.2015.06.007","article-title":"Pathogenicity of anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura","volume":"2","author":"Thomas","year":"2015","journal-title":"eBioMedicine"},{"issue":"52","key":"2025040815213738900_bib29","doi-asserted-by":"crossref","first-page":"18578","DOI":"10.1073\/pnas.1411979112","article-title":"Conformational activation of ADAMTS13","volume":"111","author":"South","year":"2014","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/7\/1728\/2367352\/blooda_adv-2024-014298-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/7\/1728\/2367352\/blooda_adv-2024-014298-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T15:53:08Z","timestamp":1744127588000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/7\/1728\/535107\/N-glycan-shielded-CUB-domains-of-ADAMTS13-prevent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,4,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014298","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]}}}